Please assess the completion status of the following clinical trial:

Trial Title: A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Chinese Postmenopausal women with ER+ HER2- locally advanced, recurrent, or metastatic breast cancer. Locally advanced breast cancer must not be amenable to curative treatment by surgery or radiotherapy.~* Histological or cytological confirmation of estrogen-receptor positive (ER+) breast cancer~* Postmenopausal women. Postmenopausal status was defined either by:~  * Prior bilateral oophorectomy~ * Or age ≥60~ * Or age \< 60 and amenorrhea for 12 or more months~* Recurrence or progression on prior NSAI was defined as:~  * Recurrence while on, or within one year (12 months) of end of adjuvant treatment with letrozole or anastrozole~ * Or Progression while on or within one month (30 days) of the end of prior treatment with letrozole or anastrozole~* Radiological or objective evidence of recurrence or progression on or after the last systemic therapy prior to enrollment~* Patient had as per RECIST 1.1~  * measurable disease or non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of measurable disease.~ * non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of measurable disease.~* Patient was able to swallow and retain oral medication~* Patient met the hematologic and biochemistery laboratory values at the screening visit~* Patient had a WHO performance status ≤2~* Written informed consent obtained prior to any screening procedures~Exclusion Criteria:~* HER2-overexpressing patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive), based on the most recent test.~* Patients who had received more than one chemotherapy line for ABC~* Patients with symptomatic visceral disease and candidates to chemotherapy~* Patients with only non-measurable lesions other than lytic or mixed (lytic and blastic) bone metastasis (e.g. pleural effusion, ascites etc.)~* Patients receiving concomitant immunosuppressive agents or chronic corticosteroids used at the time of study entry except topical applications, inhaled sprays, eye drops or local injections.~* Uncontrolled diabetes mellitus as defined by HbA1c \>7% despite adequate therapy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus + Exemestane (Type: EXPERIMENTAL): Participants received everolimus as a continuous oral daily dose of 10 mg and exemestane as a continuous oral daily dose of 25 mg
- Placebo + Exemestane (Type: ACTIVE_COMPARATOR): Participants received placebo as a continuous oral daily dose and exemestane as a continuous oral daily dose of 25 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).